FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 白花油國際有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00239 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 600,000,000 | HKD | 0.05 | HKD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 600,000,000 | HKD | | 0.05 HKD | | 30,000,000 | 本月底法定/註冊股 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 白花油國際有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00239 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 600,000,000 | HKD | | 0.05 | HKD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 600,000,000 | HKD | | 0.05 | HKD | | 30, ...

Core Viewpoint - The recent stock transfer of White Flower Oil (00239) indicates a significant movement in shareholder structure, while the company's financial performance shows a decline in revenue and profit metrics for the first half of the fiscal year ending June 30, 2025 [1] Financial Performance - The company reported revenue of HKD 94.734 million, a year-on-year decrease of 28.5% [1] - Reported profit was HKD 39.743 million, down 16.2% compared to the previous year [1] - The underlying recurring profit was HKD 45.294 million, reflecting a decrease of 26.6% year-on-year [1] - Earnings per share (EPS) for the reported profit stood at HKD 0.128 [1] Dividend Distribution - The company proposed an interim dividend of HKD 0.03 per share and a special interim dividend of HKD 0.05 per share [1]

Group 1 - The core viewpoint of the article highlights the recent stock transfer of White Flower Oil (00239) from USB Securities Hong Kong Limited to HSBC Hong Kong, with a market value of HKD 38.2361 million, representing 5.18% of the total shares [1] Group 2 - For the six-month interim results ending June 30, 2025, White Flower Oil reported revenue of HKD 94.734 million, a year-on-year decrease of 28.5% [1] - The reported profit was HKD 39.743 million, reflecting a year-on-year decline of 16.2% [1] - The underlying recurring profit was HKD 45.294 million, down 26.6% year-on-year [1] - Earnings per share for the reported profit were HKD 0.128, with a proposed interim dividend of HKD 0.03 per share and a special interim dividend of HKD 0.05 per share [1]

Key Points - As of December 19, 38 stocks reached their 52-week highs, with Li Gao Health Life (02370), Ginkgo Education (01851), and Kangqiao Yuelife (02205) leading the high rate at 36.36%, 18.72%, and 8.70% respectively [1] - The top three stocks that achieved new highs are as follows: - Li Gao Health Life (02370) closed at 0.670, with a peak of 0.750, marking a 36.36% increase - Ginkgo Education (01851) closed at 2.430, with a peak of 2.600, marking an 18.72% increase - Kangqiao Yuelife (02205) closed at 1.200, with a peak of 1.250, marking an 8.70% increase [1] - Other notable stocks that reached new highs include Liangqing Holdings (1,000) at 7.14%, Jinxing International Holdings (02307) at 7.04%, and Wuxi Life (08148) at 6.21% [1] 52-Week Low Summary - The 52-week low rankings show that Haowen Holdings (08019) had the largest decline at -16.13%, closing at 0.130 [2] - Other significant declines include NIU Holdings (08619) at -11.86%, closing at 0.156, and Hashkey HLDGS (03887) at -9.59%, with a low of 5.090 [2] - Additional stocks with notable declines include Songdu Service (09608) at -9.09%, closing at 0.068, and Ruike Bio-B (02179) at -5.41%, closing at 5.070 [2]

Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged unit bribery, which may adversely affect its brand reputation and future business development [1][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has been prosecuted for alleged unit bribery, with the prosecution materials received from the supervisory committee [1][3]. - The company is currently in the prosecution review stage and has appointed defense lawyers to handle the case [5]. Group 2: Stock Market Reaction - Following the announcement of the legal issues, Xinfeng Pharmaceutical's stock price experienced a significant increase, reaching a limit-up of 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [2]. Group 3: Company Performance - For the first three quarters of the year, Xinfeng Pharmaceutical reported a revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [8]. - The company's financial performance has been unstable, with a projected decline of over 60% in net profit attributable to shareholders for 2024 [8].

Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged corporate bribery, which may negatively impact its brand reputation and future business development [2][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has received materials for prosecution regarding alleged corporate bribery from the procuratorial organ [2][3]. - The company is currently in the prosecution review stage and will cooperate with relevant authorities while appointing defense lawyers for the case [5]. Group 2: Financial Performance - For the first three quarters of this year, Xinfeng Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55% [8]. - The net profit attributable to shareholders was 152 million yuan, down 13.74% year-on-year, with projections indicating a more than 60% decline in net profit for 2024 [8]. Group 3: Company Background - Xinfeng Pharmaceutical is primarily engaged in pharmaceutical manufacturing, including traditional Chinese medicine cultivation, new drug research and development, production, and sales, focusing on cardiovascular and digestive system products [8]. - The company has faced negative news in recent years, including a bribery case involving its subsidiary, Guizhou Keka Pharmaceutical Co., Ltd., which is 99.99% owned by Xinfeng Pharmaceutical [6].

Core Viewpoint - The company, Xinbang Pharmaceutical, is facing legal challenges due to allegations of unit bribery, which may adversely affect its brand reputation, business expansion, and future development [2][3]. Group 1: Legal Issues - Xinbang Pharmaceutical has received a notice from the prosecution regarding the review and prosecution phase of a case involving alleged unit bribery [3]. - The bribery case is linked to a merger involving Guizhou Keka Medical Co., which is 99.99% controlled by Xinbang Pharmaceutical [5]. - The case is connected to corruption within the Guizhou medical system, specifically involving former officials and the company's previous chairman [7][10]. Group 2: Financial Performance - For the first three quarters, Xinbang Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [11]. - The company's stock price experienced a sudden surge, closing at 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [2][4]. Group 3: Company Structure and Operations - Xinbang Pharmaceutical was established in January 1995 and went public in April 2010, becoming a leading pharmaceutical distribution company in Guizhou Province [11]. - The company has developed a full industry chain centered on medical services, with over 130 bases for traditional Chinese medicinal materials covering more than 270,000 acres [11]. - Despite the legal issues, the company asserts that its control structure remains unchanged, and its board and management are functioning normally [11].

Core Viewpoint - The company, Sinopharm, is facing legal challenges due to allegations of unit bribery, which may adversely affect its brand reputation, business expansion, and future development [3][10]. Group 1: Legal Proceedings - Sinopharm announced that it received a notice from the prosecution regarding the review and prosecution phase of a case involving alleged unit bribery [1][11]. - The case is linked to a bribery incident involving its subsidiary, Guizhou Kakai Pharmaceutical Co., which is 99.99% controlled by Sinopharm [5][15]. - The allegations stem from a corruption case involving Wang Xiaolin, the former deputy secretary of the Party Committee and president of Guiyang Medical College Affiliated Hospital [6][15]. Group 2: Financial Impact - As of the latest report, Sinopharm's stock price was 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [3][12]. - The company reported a revenue of 4.266 billion yuan for the first three quarters, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [9][18]. Group 3: Company Operations - Despite the ongoing legal issues, the company stated that its control structure remains unchanged, and its board and management are functioning normally [10][19]. - Sinopharm has established a comprehensive "medical services+" industry chain, focusing on medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing [9][18].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 白花油國際有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年12月1日 第 2 頁 共 10 頁 v 1.1.1 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00239 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 311,640,000 | | 0 | | 311,640,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 311,640,000 | | 0 | | 311,640,000 | | 1. 股份分類 ...